Content about Anemia

October 31, 2012
Sandoz starts phase-3 trial of biosimilar anemia drug

Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

HOLZKIRCHEN, Germany — Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, said it had started enrolling patients for a phase-3 study of epoetin alfa, a biosimilar version of Epogen and Procrit, made by Amgen and Johnson & Johnson and used to treat anemia associated with chronic kidney disease.

April 20, 2012
Two strategies for managing anemia in hepatitis C patients work equally well, Merck says

Merck is testing two means of treating patients with chronic hepatitis C for anemia, a common side effect of certain treatments for the viral infection, the drug maker said.

BARCELONA, Spain — Merck is testing two means of treating patients with chronic hepatitis C for anemia, a common side effect of certain treatments for the viral infection, the drug maker said.

Merck announced results of a phase-3 study comparing two strategies for managing anemia and how they affect the curing of hepatitis C in patients taking Victrelis (boceprevir) with Pegintron (peginterferon alfa-2b) and ribavirin.

March 28, 2012
FDA approves Omontys for kidney disease-related anemia

The Food and Drug Administration has approved a new treatment for anemia in patients with chronic kidney disease.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for anemia in patients with chronic kidney disease.

The FDA announced the approval of Affymax's Omontys (peginesatide), a drug belonging to the class known as erythropoiesis-stimulating agents, designed to aid the formation of red blood cells.

March 12, 2012
Watson starts phase-3 trial of Esmya

Drug maker Watson Pharmaceuticals has started a late-stage trial of a drug made to treat benign tumors of the uterus, the company said Monday.

PARSIPPANY, N.J. — Drug maker Watson Pharmaceuticals has started a late-stage trial of a drug made to treat benign tumors of the uterus, the company said Monday.

Watson announced the initiation of a phase-3 trial of Esmya (ulitristal acetate) in women who have anemia due to uterine leimyomas, also known as uterine fibroids, which causes benign solid tumors that can lead to excessive menstrual bleeding, anemia and pain and may require surgery. Watson is developing the drug under a licensing agreement with Gedeon Richter.

November 16, 2011
FDA approves drug for rare bone marrow disorder

The Food and Drug Administration has approved a new drug for treating a rare bone disease, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare bone marrow disease, the agency said Wednesday.

October 14, 2011
FDA approves treatment for iron overload

The Food and Drug Adminsitration has approved a drug made by ApoPharma for a complication resulting from treatments for a genetic condition that causes anemia, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Adminsitration has approved a drug made by ApoPharma for a complication resulting from treatments for a genetic condition that causes anemia, the agency said Friday.

The FDA announced the approval of Ferriprox (deferiprone), used to treat patients with iron overload due to blood transfusions for thalassemia, a blood disorder. Patients with the disease have excess iron in their bodies because of the frequent blood transfusions they must receive that can lead to iron overload, a condition that can be fatal.

April 1, 2011
Watson receives FDA approval for Nulecit

The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.

The drug maker announced the approval of Nulecit (sodium ferric gluconate complex in sucrose), an injectable and generic version of Sanofi-Aventis’ Ferrlecit.

The drug is used to treat iron deficiency anemia in adults and children ages 6 years and older undergoing chronic hemodialysis and receiving supplemental epoetin therapy.

October 25, 2010
Strativa enters license, supply agreement with Sobi

Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription...

WOODCLIFF LAKE, N.J. Strativa Pharmaceuticals is working with a Swedish drug maker to develop and commercialize a prescription vitamin supplement, Strativa said Tuesday.

 

The company said it had signed a license and supply agreement with Swedish Orphan Biovitrum, also known as Sobi, concerning European rights to Strativa’s Nascobal (cyanocobalamin), a vitamin B12 nasal spray.

 

 

September 23, 2010
Amgen recalls certain lots of Epogen, Procrit

Several lots of two drugs used to treat anemia are being recalled due to possible...

THOUSAND OAKS, Calif. Several lots of two drugs used to treat anemia are being recalled due to possible contamination.

 

Amgen said Friday that it was voluntarily recalling certain lots of Epogen and Procrit (epoetin alfa) from distributors, wholesalers, healthcare providers and pharmacies as a precaution due to the possible presence of extremely thin and barely visible glass flakes known as lamellae that result from an interaction between the drugs and the glass vials used to store them.